Drugs /

ivuxolimab

Back to Drugs List

Overview

NCI Definition [1]:
An agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, ivuxolimab selectively binds to and activates OX40; which induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation.

Clinical Trials

View Clinical Trials for ivuxolimab

Ivuxolimab has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating ivuxolimab, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for ivuxolimab clinical trials.

Acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, and bladder carcinoma are the most common diseases being investigated in ivuxolimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ivuxolimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ivuxolimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pf-8600, anti-ox40 antibody pf-04518600, pf-04518600, anti-ox40 agonist monoclonal antibody pf-04518600, pf04518600
Drug Target(s) [2]:
TNFRSF4
NCIT ID [1]:
C121927

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.